This clinical trial is focused on studying how different forms of the study medicine, tafamidis, are absorbed into the blood in healthy adults. Tafamidis is a medication used to treat a heart condition known as transthyretin amyloid cardiomyopathy, which affects the heart’s ability to function properly. The study will compare the absorption of two different tablet forms of tafamidis (61 mg and 70 mg) to a capsule form (61 mg) when taken by healthy participants who have not eaten.
The purpose of the study is to estimate how well the body absorbs these different forms of tafamidis. Participants will receive a single dose of each form of the medication in a randomized order, meaning the order in which they receive the tablets and capsule will be determined by chance. The study will take place over three periods, with each participant receiving all three forms of the medication at different times. This approach helps researchers understand the differences in how the body takes up each form of the medication.
Throughout the study, participants will be monitored to measure the levels of tafamidis in their blood. This information will help determine the relative bioavailability, which is a term used to describe how much of the drug enters the bloodstream and is available to have an effect. The study is designed to ensure the safety and well-being of participants while providing valuable information about the medication’s absorption in the body.
Belgium 
